"...it will take good results from sales" - you mean after the drugs go through clinical trials successfully, then FDA approval, then sales, THEN the pps rises?
My friend, you'd miss out on virtually every screamer of a biotech stock in the history of biotechs if you waited until sales revenues.
You know how much Kite Pharma had in sales revs before getting acquired? $0.00
All their stuff was preclinical, except one that was in early P1.
Know what Kite was acquired for? $12 billion.
Regen doesn't need anything even close to Kite's valuation to warrent massive pps increases from the .02 levels.
News 
Market Data 
Discover 
